Nucleic acid amplification technology methods used in blood donor screening

Transfusion Medicine

Volumn 12, Issue 4, 2002, Pages 229-242

  Grant, P R ^a   Busch, M P ^b,c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b Blood Centers of the Pacific   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACID; VIRUS RNA;

BLOOD DONOR; BLOOD STORAGE; GENE AMPLIFICATION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NONHUMAN; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCREENING TEST; TRANSCRIPTION REGULATION; VIRUS INFECTION;

BLOOD DONORS; HUMANS; INFECTION; INFECTION CONTROL; MASS SCREENING; NUCLEIC ACID AMPLIFICATION TECHNIQUES; REAGENT KITS, DIAGNOSTIC;

EID: 0036674645     PISSN: 09587578     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3148.2002.00382.x     Document Type: Review

References (80)

1. Assay formats involving acridinium-ester-labeled DNA probes
2. Genetic disease detection and DNA amplification using cloned thermostable ligase
3. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA
4. Evaluation of automated RNA-extraction technology and a qualitative HCV assay for sensitivity and detection of HCV RNA in pool-screening systems
5. Rapid and simple method for purification of nucleic acids
6. NAT and blood safety: What is the paradigm?
7. Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion
8. HCV RNA and ALT patterns in seroconverting transfusion recipients, and correlation with donor ALT and RNA
9. Evolving applications of nucleic acid amplification assays for prevention of viral transmission by blood components and derivatives
10. Impact of specimen handling and storage on detection of hepatitis C virus RNA
11. The first case of HCV seroconversion after 3 years of HCVNAT screening in Baden-Wurttemberg
12. Experiences in HCV-NAT screening prior to releasing cellular components by the German Red Cross Blood Transfusion Service of Baden-Wurttemberg
13. Minipool screening by nucleic acid testing for hepatitis B virus, hepatitis C virus, and HIV: Preliminary results
14. Outbreak of hepatitis C associated with intravenous immunoglobulin administration - United States, October 1993-June 1994
15. Emerging infectious agents: Do they pose a risk to the safety of transfused blood and blood products?
16. Development of multiplexed nucleic acid testing for human immunodeficiency virus type 1 and hepatitis C virus
17. Nucleic acid sequence-based amplification
18. Intramuscular immunoglobulins: Nucleic acid amplification tests for HCV RNA detection
19. Validation of the NucliSens Extractor in combination with the hepatitis C virus Cobas Amplicor 2.0 assay in four laboratories in The Netherlands utilizing nucleic acid Amplification technology for blood screening
20. Characteristics and applications of nucleic acid sequence-based amplification (NASBA)
21. COBAS AMPLICOR: Fully automated RNA and DNA amplification and detection system for routine diagnostic PCR
22. TaqMan 5′-nuclease human immunodeficiency virus type 1 PCR assay with phage-packaged competitive internal control for high-throughput blood donor screening
23. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology (International Forum)
24. FDA approves first nucleic acid test (NAT) system to screen whole blood donors for infections with human immunodeficiency virus (HIV) and hepatitis C virus (HCV)
25. Detection of hepatitis C viral sequences in blood donations by 'nested' polymerase chain reaction and prediction of infectivity
26. Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay
27. Gammagard and reported hepatitis C virus episodes
28. Automated screening of blood donations for Hepatitis C Virus RNA using the Qiagen BioRobot 9604 and the Roche COBAS HCV Amplicor assay
29. A novel RT-PCR for reliable and rapid HCV RNA screening of blood donations
30. Kinetic PCR analysis: Real-time monitoring of DNA amplification reactions
31. Detection of specific polymerase chain reaction product by utilizing the 5′ - 3′ Exonuclease activity of Thermus aquaticus DNA polymerase
32. An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques
33. Screening blood donations for hepatitis C virus by polymerase chain reaction
34. Validation of the NucliSens Extractor combined with the AmpliScreen HIV v1.5 and HCV v2.0 test for application in NAT minipool screening
35. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection
36. The risks of transfusion-transmitted infection: Direct estimation and mathematical modelling
37. Estimated risk of transmission of hepatitis C virus by blood transfusion
38. Detection of hepatitis B virus sequences in serum by using in vitro enzymatic amplification
39. Allelic discrimination by nick-translation PCR with fluorogenic probes
40. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: Calibration to international units, enhanced genotype reactivity, and performance characteristics
41. Quality assessment of hepatitis C virus nucleic acid amplification methods - An international proficiency study
42. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period
43. Sensitive detection of genetic variants of HIV-1 and HCV with an HIV-1/HCV assay based on transcription-mediated amplification
44. Detection of cytomegalovirus in plasma and cerebrospinal fluid specimens from human immunodeficiency virus-infected patients by the AMPLICOR CMV test
45. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions
46. High throughput assay for the simultaneous or separate detection of human immunodeficiency virus (HIV) and hepatitis type C virus (HCV)
47. Automated multiplex assay system for simultaneous detection of hepatitis B virus DNA, hepatitis C virus RNA, and human immunodeficiency virus type 1 RNA
48. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction
49. Redefining the HIV-infectious window period in the chimpanzee model: Evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission
50. Reverse transcription and DNA amplification by a Thermus thermophilus DNA polymerase
51. Simultaneous detection of multiple nucleic acid targets in a homogeneous format
52. DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells
53. Results of the phased plan to reduce the infection risk in Hepatitis B, C, and HIV in recipients of packed red cell transfusions
54. Improved COBAS AMPLICOR (TM) viral assays as a basis for minipool screening of viruses in blood or plasma
55. An internal control for routine diagnostic PCR: Design, properties, and effect on clinical performance
56. Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe
57. Nucleic acid testing (NAT) for hepatitis B virus and anti-HBc testing increase blood safety
58. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting
59. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques
60. Calibration of HCV working reagents for NAT assays against the HCV international standard
61. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA
62. Establishment of the first World Health Organization international standard for human parvovirus B19 DNA nucleic acid amplification techniques
63. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study
64. Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA
65. Introduction of nucleic acid amplification testing of plasma pools - Implications for an integrated blood service
66. The risks of infection transmission by blood transfusion in England
67. NAT of the United States and Canadian blood supply
68. Experience with PCR screening
69. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma
70. Simultaneous extraction of hepatitis C virus (HCV), hepatitis B virus, and HIV-1 from plasma and detection of HCV RNA by a reverse transcriptase-polymerase chain reaction assay designed for screening pooled units of donated blood
71. Synthesis and characterization of branched DNA (bDNA) for the direct and quantitative detection of CMV, HBV, HCV, and HIV
72. The NucliSens (TM) Extractor for automated nucleic acid isolation
73. Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA
74. Evaluation of a new HTLV-I/II polymerase chain reaction
75. Serious hazards of transfusion (SHOT) initiative: Analysis of the first two annual reports
76. Advances in nucleic acid-based detection methods
77. The ligation amplification reaction (LAR) - Amplification of specific DNA sequences using sequential rounds of templatedependent ligation
78. Performance characteristics of the AmpliScreen HIV-1 test, an assay designed for screening plasma mini-pools
79. Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay